Common Stock, par value $0.001
- Symbol
- BTAI
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Historical · closed Sep 4, 2026
Current Report · Items 1.01, 9.01 · 8-K
BioXcel Therapeutics, Inc.
Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On August 21, 2026, BioXcel Therapeutics, Inc. (the “Company”) entered into the Thirteenth Amendment to Credit Agreement and Guaranty (the “Thirteenth Amendment”), which amended the Credit Agreement and Guaranty, dated April 19, 2022, as amended (the “Credit Agreement”), by and among the Company, as the borrower, certain subsidiaries of the Com…
Company context
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit bioxceltherapeutics.com.
Current securities
Historical securities (1)
Recent company filings
- Completion of Acquisition or Disposition of Assets · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearOct 30, 2026
- Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingSep 1, 2026
- Entry into a Material Definitive Agreement · Bankruptcy or ReceivershipAug 28, 2026
- Entry into a Material Definitive AgreementAug 25, 2026
- 10-Q filingAug 13, 2026
Registered securities in this filing
BioXcel Therapeutics, Inc. · 8-K · Filed 2026-08-24
Disclosure sections
Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Agreement.
On August 21, 2026, BioXcel Therapeutics, Inc. (the “Company”) entered into the Thirteenth Amendment to Credit Agreement and
Guaranty (the “Thirteenth Amendment”), which amended the Credit Agreement and Guaranty, dated April 19, 2022, as amended (the
“Credit Agreement”), by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party
thereto as subsidiary guarantors, the lenders party thereto (the “Lenders”), and Oaktree Fund Administration LLC, as administrative
agent.
Pursuant to the Thirteenth Amendment, the Company is required to, on or prior to August 28, 2026 (extended from August 21, 2026, as was
required under the Twelfth Amendment), enter into definitive agreements with respect to one or more transactions acceptable to Lenders
that (A) would result in the repayment of all loan and other obligations under the Credit Agreement or (B) is an alternative capital solutions
transaction on terms and conditions acceptable to the Lenders.
The foregoing summary of the Thirteenth Amendment is qualified in its entirety by the complete text of such agreement, a copy of which
is filed hereto as Exhibits 10.1.